JP2012500264A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500264A5
JP2012500264A5 JP2011523833A JP2011523833A JP2012500264A5 JP 2012500264 A5 JP2012500264 A5 JP 2012500264A5 JP 2011523833 A JP2011523833 A JP 2011523833A JP 2011523833 A JP2011523833 A JP 2011523833A JP 2012500264 A5 JP2012500264 A5 JP 2012500264A5
Authority
JP
Japan
Prior art keywords
composition according
treating
condition
neurodegeneration
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011523833A
Other languages
English (en)
Japanese (ja)
Other versions
JP5773870B2 (ja
JP2012500264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040766 external-priority patent/WO2010021766A1/en
Publication of JP2012500264A publication Critical patent/JP2012500264A/ja
Publication of JP2012500264A5 publication Critical patent/JP2012500264A5/ja
Application granted granted Critical
Publication of JP5773870B2 publication Critical patent/JP5773870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011523833A 2008-08-21 2009-04-16 ヒドロキシ酪酸エステル及びその医学的使用 Active JP5773870B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9075108P 2008-08-21 2008-08-21
US61/090,751 2008-08-21
PCT/US2009/040766 WO2010021766A1 (en) 2008-08-21 2009-04-16 Hydroxybutyrate ester and medical use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014241939A Division JP6092836B2 (ja) 2008-08-21 2014-11-28 ヒドロキシ酪酸エステル及びその医学的使用

Publications (3)

Publication Number Publication Date
JP2012500264A JP2012500264A (ja) 2012-01-05
JP2012500264A5 true JP2012500264A5 (cg-RX-API-DMAC10.html) 2012-06-07
JP5773870B2 JP5773870B2 (ja) 2015-09-02

Family

ID=40885956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011523833A Active JP5773870B2 (ja) 2008-08-21 2009-04-16 ヒドロキシ酪酸エステル及びその医学的使用
JP2014241939A Active JP6092836B2 (ja) 2008-08-21 2014-11-28 ヒドロキシ酪酸エステル及びその医学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014241939A Active JP6092836B2 (ja) 2008-08-21 2014-11-28 ヒドロキシ酪酸エステル及びその医学的使用

Country Status (10)

Country Link
EP (3) EP3296284B1 (cg-RX-API-DMAC10.html)
JP (2) JP5773870B2 (cg-RX-API-DMAC10.html)
CN (1) CN102164884B (cg-RX-API-DMAC10.html)
AU (1) AU2009283171B2 (cg-RX-API-DMAC10.html)
CA (1) CA2734720C (cg-RX-API-DMAC10.html)
DK (2) DK2328858T3 (cg-RX-API-DMAC10.html)
ES (2) ES2655367T3 (cg-RX-API-DMAC10.html)
NO (1) NO2328858T3 (cg-RX-API-DMAC10.html)
PL (2) PL2328858T3 (cg-RX-API-DMAC10.html)
WO (1) WO2010021766A1 (cg-RX-API-DMAC10.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
WO2009089144A1 (en) 2008-01-04 2009-07-16 Isis Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) * 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) * 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
GB2515603B (en) * 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
CA2973342A1 (en) * 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
CN103860533A (zh) * 2014-02-12 2014-06-18 新乡医学院 β羟基丁酸在治疗帕金森病中的应用
WO2015140752A1 (en) * 2014-03-19 2015-09-24 Stellenbosch University Method for treating or enhancing muscle tissue
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
RU2761829C2 (ru) 2016-06-07 2021-12-13 Зе Дж. Дэвид Глэдстоун Инститьютс Образуемые среднецепочечными жирными кислотами сложные эфиры бета-гидроксибутирата и бутандиола и композиции и способы на их основе
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
MX390420B (es) * 2016-12-23 2025-03-20 Univ Leuven Kath 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos.
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
BR112020001285A2 (pt) * 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
GB201715654D0 (en) * 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
GB2575623B (en) * 2018-06-04 2022-10-26 Tdeltas Ltd 3-hydroxybutyrate esters for treating cancer cachexia
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
BR112020023132A2 (pt) 2018-06-21 2021-02-09 Société des Produits Nestlé S.A. composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
GB2577723A (en) * 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
WO2020147979A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von polyolbasierten estern von hydroxycarbonsäuren
CN109700021A (zh) * 2019-03-04 2019-05-03 清华大学 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用
AU2020274805A1 (en) 2019-05-10 2021-10-28 Ketoswiss Ag Ketone bodies enclosed in microbeads
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CA3135099A1 (en) * 2019-05-21 2020-11-26 Societe Des Produits Nestle S.A. Dietary butyrate
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
ES2969217T3 (es) * 2019-06-12 2024-05-17 Ketolipix Therapeutics Gmbh Procedimiento para la producción de ésteres a base de poliol, en particular ésteres de poliglicerol, de ácidos hidroxicarboxílicos
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
WO2021195477A1 (en) * 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
WO2021231271A1 (en) * 2020-05-12 2021-11-18 Genomatica, Inc. Process of synthesizing and purifying (3r)-hydroxybutyl (3r)-hydroxybutanoate
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
EP4146339B1 (de) * 2020-07-13 2024-04-10 KetoLipix Therapeutics GmbH Oxobutanol-ester von polymeren carbonsäuren und deren herstellung
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113045416B (zh) * 2021-03-23 2023-08-18 南京纽邦生物科技有限公司 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
US20250275986A1 (en) 2021-07-17 2025-09-04 Ketoswiss Ag Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
IT202100020441A1 (it) 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1051853B (it) * 1975-01-07 1981-05-20 Basf Ag Butandiol 1.3 3 mono 3 idros sibutirrati butandiol 1.3 1mono 3 idrossibutirrati e processi per la loro preparazione
JPH0755158B2 (ja) * 1986-10-30 1995-06-14 チッソ株式会社 光学活性エステルの製造法
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
ES2574918T3 (es) 2003-06-02 2016-06-23 Isis Innovation Limited Tratamiento de la fatiga muscular
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
JP5145240B2 (ja) * 2005-11-29 2013-02-13 ビーエーエスエフ ソシエタス・ヨーロピア ポリマー中の側鎖をエステル交換またはエステル化する方法
US8452351B2 (en) * 2008-06-02 2013-05-28 Qualcomm Incorporated Methods and apparatus for saving battery power in mobile stations

Similar Documents

Publication Publication Date Title
JP2020527583A5 (cg-RX-API-DMAC10.html)
PH12020500169B1 (en) Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
JP5714227B2 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
JP2009533356A5 (cg-RX-API-DMAC10.html)
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2008054200A3 (en) Use of nutritional compositions for preventing disorders
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
EP2875736B1 (en) N-Carbamoylputrescine to enhance muscle protein synthesis
RU2015129066A (ru) Применение bifidobacterium animalis для лечения или предотвращения набора веса и инсулинорезистентности
WO2010080756A3 (en) Harmine derivatives for reducing body weight
IN2012DN02590A (cg-RX-API-DMAC10.html)
EP4410833A3 (en) Compositions and methods for treating fatty tissue buildup
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
FI4349369T3 (fi) Lääkkeen biologisen hyötyosuuden lisääminen naltreksonihoidossa
JP2007504168A5 (cg-RX-API-DMAC10.html)
JP2024513567A (ja) 1-メチルキサンチンをベースにした生物活性組成物およびそれを使用する方法
WO2010107866A3 (en) Catecholamine derivatives for obesity and neurological disorders
JP2012509669A5 (cg-RX-API-DMAC10.html)
JP2019062914A (ja) アンモニア代謝促進剤
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
WO2018093237A3 (ko) 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
EP2504006B1 (en) Compositions comprising amino acids for treating chronic obstructive pulmonary disease
JP5557243B2 (ja) 睡眠の改善剤
US20170340587A1 (en) N-carbamoylputrescine to enhance muscle protein synthesis